Literature DB >> 17229185

Non-nucleoside reverse transcriptase inhibitors: a review.

L Waters1, L John, M Nelson.   

Abstract

Non-nucleoside reverse transcriptase inhibitors form the backbone of antiretroviral treatment for many HIV-infected individuals. The tolerability, pill burden and efficacy associated with this class of agents make them a frequent choice for first-line therapy. Here we review nevirapine and efavirenz in terms of efficacy, resistance and toxicity, focusing particularly on the use of nevirapine to prevent mother-to-child transmission in developing countries.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17229185     DOI: 10.1111/j.1742-1241.2006.01146.x

Source DB:  PubMed          Journal:  Int J Clin Pract        ISSN: 1368-5031            Impact factor:   2.503


  10 in total

1.  Evaluation of anti-HIV-1 mutagenic nucleoside analogues.

Authors:  Valérie Vivet-Boudou; Catherine Isel; Yazan El Safadi; Redmond P Smyth; Géraldine Laumond; Christiane Moog; Jean-Christophe Paillart; Roland Marquet
Journal:  J Biol Chem       Date:  2014-11-14       Impact factor: 5.157

2.  In vitro and in vivo activities of AIC292, a novel HIV-1 nonnucleoside reverse transcriptase inhibitor.

Authors:  Steffen Wildum; Daniela Paulsen; Kai Thede; Helga Ruebsamen-Schaeff; Holger Zimmermann
Journal:  Antimicrob Agents Chemother       Date:  2013-08-19       Impact factor: 5.191

Review 3.  Etravirine: a review of its use in the management of treatment-experienced patients with HIV-1 infection.

Authors:  Jamie D Croxtall
Journal:  Drugs       Date:  2012-04-16       Impact factor: 9.546

4.  Protein adducts as prospective biomarkers of nevirapine toxicity.

Authors:  Alexandra M M Antunes; Ana L A Godinho; Inês L Martins; M Conceição Oliveira; Ricardo A Gomes; Ana V Coelho; Frederick A Beland; M Matilde Marques
Journal:  Chem Res Toxicol       Date:  2010-09-01       Impact factor: 3.739

5.  No evidence for induction of ABC transporters in peripheral blood mononuclear cells in humans after 14 days of efavirenz treatment.

Authors:  Jürgen Burhenne; Anne-Kathrin Matthée; Ivana Pasáková; Claudia Röder; Tilman Heinrich; Walter Emil Haefeli; Gerd Mikus; Johanna Weiss
Journal:  Antimicrob Agents Chemother       Date:  2010-07-26       Impact factor: 5.191

6.  C-2-aryl O-substituted HI-236 derivatives as non-nucleoside HIV-1 reverse-transcriptase inhibitors.

Authors:  Roger Hunter; Yassir Younis; Clare I Muhanji; Tanith-Lea Curtin; Kevin J Naidoo; Melissa Petersen; Christopher M Bailey; Aravind Basavapathruni; Karen S Anderson
Journal:  Bioorg Med Chem       Date:  2008-11-01       Impact factor: 3.641

7.  Prevalence of transmitted drug resistance and impact of transmitted resistance on treatment success in the German HIV-1 Seroconverter Cohort.

Authors:  Barbara Bartmeyer; Claudia Kuecherer; Claudia Houareau; Johanna Werning; Kathrin Keeren; Sybille Somogyi; Christian Kollan; Heiko Jessen; Stephan Dupke; Osamah Hamouda
Journal:  PLoS One       Date:  2010-10-07       Impact factor: 3.240

8.  Mild palladium-catalyzed cyanation of (hetero)aryl halides and triflates in aqueous media.

Authors:  Daniel T Cohen; Stephen L Buchwald
Journal:  Org Lett       Date:  2015-01-02       Impact factor: 6.005

9.  Efficacy and safety of switching from nevirapine immediate-release twice daily to nevirapine extended-release once daily in virologically suppressed HIV-infected patients: a retrospective cohort study in Taiwan.

Authors:  Chun-Yuan Lee; Hui-Min Chang; Calvin M Kunin; Susan Shin-Jung Lee; Yao-Shen Chen; Hung-Chin Tsai
Journal:  BMC Infect Dis       Date:  2017-04-11       Impact factor: 3.090

10.  2'-Deoxythymidine adducts from the anti-HIV drug nevirapine.

Authors:  Alexandra M M Antunes; Benjamin Wolf; M Conceição Oliveira; Frederick A Beland; M Matilde Marques
Journal:  Molecules       Date:  2013-04-26       Impact factor: 4.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.